Merck Sharp & Dohme LLC
The goal of this trial is to measure what happens to 1 or 2 doses of MK-2828 in a person's body over time (pharmacokinetic or PK trial). Researchers want to learn if the PK of people with certain types of kidney disease is similar to the PK of healthy people.
The main inclusion criteria include but are not limited to the following: * Is in generally good health, with the exception of renal impairment participants. Participants with stable, chronic medical or psychiatric conditions may be included at the discretion of the investigator and the Sponsor. Severe Renal Impairment Participants: * Has an estimated glomerular filtration rate (eGFR) \< 30 mL/min), but is not on hemodialysis (HD) ESRD on HD Participants: * Has ESRD maintained on stable outpatient regimen of intermittent high-flux HD at a healthcare center for \> 3 months prior to study e…
Oral administration
Arctuva estimate
Verify or correct the compensation shown for this listing.